| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1992;54:725-731
© 1992 The Society of Thoracic Surgeons
a Institute for Experimental Medical Research and Department of Surgery, Ullevaal Hospital, Oslo, Norway
b Institute of Immunology and Rheumatology, The National Hospital, Oslo, Norway
Accepted for publication February 19, 1992.
* Address reprint requests to Dr Videm, Institute for Experimental Medical Research, Ullevaal Hospital, N-0407 Oslo 4, Norway.
Fifty-one patients admitted for routine coronary bypass operations were randomized to cardiopulmonary bypass with a membrane oxygenator (Capiox) or a bubbler (Polystan or William Harvey). Complement activation was measured using enzyme immunoassays for concentrations of C3 activation products and the terminal complement complex. From 5.8 to 8.1 arbitrary units (AU)/mL (medians), the plasma concentrations of C3 activation products increased by 119.9 AU/mL (Capiox), 124.6 AU/mL (Polystan), and 79.5 AU/mL (William Harvey) to a peak at closure of the sternum (not significant when related to baseline concentrations). The increase in C3 activation products and baseline C3 activation were linearly correlated (R 2 = 0.30; p < 0.0001). From 5.5 to 6.1 AU/mL, the plasma terminal complement complex concentrations increased by 45.2 AU/mL (Capiox), 15.4 AU/mL (Polystan), and 17.4 AU/mL (William Harvey) to a peak before termination of cardiopulmonary bypass. Maximal terminal (C5–C9) activation was significantly higher in the membrane oxygenator group (p < 0.0001) and showed no relationship to C3 activation. Measurement of C3 activation only gives no information about C5–C9 activation. At present, terminal complement complex quantitation is probably the best index of C5–C9 activation during cardiopulmonary bypass.
This article has been cited by other articles:
|
|
 |
|
  A. Thiara, T. Mollnes, V. Videm, V. Andersen, K. Svennevig, S. Kolset, and A. Fiane Biocompatibility and pathways of initial complement pathway activation with Phisio- and PMEA-coated cardiopulmonary bypass circuits during open-heart surgery Perfusion, March 1, 2011; 26(2): 107 - 114. [Abstract] [PDF]
|
|
|
|
|
|
K Svennevig, T. Hoel, A. Thiara, S. Kolset, A Castelheim, T. Mollnes, F Brosstad, E Fosse, and J. Svennevig Syndecan-1 plasma levels during coronary artery bypass surgery with and without cardiopulmonary bypass Perfusion, May 1, 2008; 23(3): 165 - 171. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Risnes, T. Ueland, P. Aukrust, R. Lundblad, S. T. Baksaas, T. E. Mollnes, and J. L. Svennevig Complement activation and cytokine and chemokines release during mediastinitis Ann. Thorac. Surg., March 1, 2003; 75(3): 981 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Hennein Inflammation After Cardiopulmonary Bypass: Therapy for the Postpump Syndrome Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 236 - 255. [Abstract] [PDF]
|
|
|
|
|
|
G Matheis, M Scholz, J Gerber, U Abdel-Rahman, G Wimmer-Greinecker, and A Moritz Leukocyte filtration in the early reperfusion phase on cardiopulmonary bypass reduces myocardial injury Perfusion, January 1, 2001; 16(1): 43 - 49. [Abstract] [PDF]
|
|
|
|
 |
|
 R. L. Korn, C. A. Fisher, E. R. Livingston, N. Stenach, S. J. Fishman, V. Jeevanandam, and V. P. Addonizio THE EFFECTS OF CARMEDA BIOACTIVE SURFACE ON HUMAN BLOOD COMPONENTS DURING SIMULATED EXTRACORPOREAL CIRCULATION J. Thorac. Cardiovasc. Surg., May 1, 1996; 111(5): 1073 - 1084. [Abstract] [Full Text]
|
|
|
|
|
|
A. Finn, B. P. Morgan, N. Rebuck, N. Klein, C. A. Rogers, M. Hibbs, M. Elliott, D. F. Shore, T. W. Evans, S. Strobel, et al. EFFECTS OF INHIBITION OF COMPLEMENT ACTIVATION USING RECOMBINANT SOLUBLE COMPLEMENT RECEPTOR 1 ON NEUTROPHIL CD11B/CD18 AND L-SELECTIN EXPRESSION AND RELEASE OF INTERLEUKIN-8 AND ELASTASE IN SIMULATED CARDIOPULMONARY BYPASS J. Thorac. Cardiovasc. Surg., February 1, 1996; 111(2): 451 - 459. [Abstract] [Full Text]
|
|
|
|
|
|
J. de Haan, P. W. Boonstra, N. Tabuchi, W. van Oeveren, and T. Ebels RETRANSFUSION OF THORACIC WOUND BLOOD DURING HEART SURGERY OBSCURES BIOCOMPATIBILITY OF THE EXTRACORPOREAL CIRCUIT J. Thorac. Cardiovasc. Surg., January 1, 1996; 111(1): 272 - 275. [Full Text]
|
|
|
|
|
|
O. Moen, E. Fosse, V. Brockmeier, C. Andersson, T. E. Mollnes, K. Hogsen, and P. Venge Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems Ann. Thorac. Surg., November 1, 1995; 60(5): 1317 - 1323. [Abstract] [PDF]
|
|
|
|
|
|
J. Gonzalez, T. Morrissey, T. Byrne, R. Rizzo, and D. Wilmore Bioelectric impedance detects fluid retention in patients undergoing cardipulmonary bypass J. Thorac. Cardiovasc. Surg., July 1, 1995; 110(1): 111 - 118. [Abstract] [Full Text]
|
|
|
|
|
|
M. Pekna, L. Hagman, E. Halden, U. R. Nilsson, B. Nilsson, and S. Thelin Complement activation during cardiopulmonary bypass: Effects of immobilized heparin Ann. Thorac. Surg., August 1, 1994; 58(2): 421 - 424. [Abstract] [PDF]
|
|
|
|
|
|
A. M. Gillinov, J. A. Winkelstein, A. Herskowitz, and D. E. Cameron Reply Ann. Thorac. Surg., March 1, 1994; 57(3): 782 - 782. [PDF]
|
|
|
|
|
|
J. Butler, G. M. Rocker, and S. Westaby Plasma C3a and C5a concentrations during cardiopulmonary bypass Reply Ann. Thorac. Surg., March 1, 1994; 57(3): 783 - 783. [PDF]
|
|
|
|
|
|
Z. A Varga Autologous plateletpheresis in cardiac surgery Perfusion, November 1, 1993; 8(6): 471 - 476. [Abstract] [PDF]
|
|
|
|
|
|
V. Videm, E. Fosse, and J. L Svennevig Platelet preservation during coronary bypass surgery with bubble and membrane oxygenators: effect of albumin priming Perfusion, September 1, 1993; 8(5): 409 - 415. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
